Enhancement of Impaired Olfactory Neural Activation and Cognitive Capacity by Liraglutide, but Not Dapagliflozin or Acarbose, in Patients With Type 2 Diabetes: A 16-Week Randomized Parallel Comparative Study.
Objective: The comparative neuroprotective effects of different antidiabetes drugs have not been characterized in randomized controlled trials. Here, we investigated the therapeutic effects of liraglutide, dapagliflozin, or acarbose treatment on brain functional alterations and cognitive changes in...
| Publicado en: | Diabetes Care Vol. 45; no. 5; pp. 1201 - 1211 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | diagnostic images research tables/charts randomized controlled trial Journal Article |
| Publicado: |
American Diabetes Association
May2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |